Interestingly, there was a modest increase in tumor-infiltrating CD8+ T cells in ICVB-1042-treated mice compared to control, suggesting that lysis of tumor cells by ICVB-1042 following IV administration can enhance recruitment and/or activation of CD8+ T cells in tumor microenvironments. This evidence concerns the gene CD8A and neoplasm.